Cardiology Medical News about Atherosclerosis Garlic

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial
Preventive Medicine, 10/08/09

Budoff MJ et al. – Aged garlic extract therapy with supplements (AGE + S) is associated with a favorable improvement in oxidative biomarkers, vascular function, and reduced progression of atherosclerosis.

Methods

In this placebo–controlled, double–blind, randomized trial (conducted 2005–2007), 65 intermediate risk patients (age 60 ± 9 years, 79% male) were treated with a placebo capsule or a capsule containing aged garlic extract (250 mg) plus Vitamin B12 (100 microg), folic acid (300 microg), Vitamin B6 (12.5 mg) and l–arginine (100 mg) given daily for a 1 year.
All patients underwent coronary artery calcium scanning (CAC), temperature rebound (TR) as an index of vascular reactivity using Digital Thermal Monitoring (DTM), and measurement of lipid profile, autoantibodies to malondialdehyde (MDA)–LDL, apoB–immune complexes, oxidized phospholipids (OxPL) on apolipoprotein B–100 (OxPL/apoB), lipoprotein (a) [Lp (a)], C–reactive protein (CRP), homocysteine were measured at baseline and 12 months.
CAC progression was defined as an increase in CAC > 15% per year and an increase in TR above baseline was considered a favorable response.

Results

At 1 year, CAC progression was significantly lower and TR significantly higher in the AGE + S compared to the placebo group after adjustment of cardiovascular risk factors.
Total cholesterol, LDL–C, homocysteine, IgG and IgM autoantibodies to MDA–LDL and apoB–immune complexes were decreased, whereas HDL, OxPL/apoB, and Lp (a) were significantly increased in AGE + S to placebo.

<< Previous
Review: combining 2 classes of blood pressure-lowering drugs has...

Next >>
Bosentan: A Review of its Use in the Management of Mildly...